Indivior Plc (INDV) - Financial and Strategic SWOT Analysis Review

October 2021 | 59 pages | ID: IE0F68CAF91EN
GlobalData

Abstracts

Indivior Plc (INDV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Indivior Plc (Indivior) develops and markets medicines for the treatment of opioid addiction. The company offers suboxone a monthly depot, and only approved film treatment for opioid dependence; subutex, a mono-buprenorphine sublingual tablet, sublocad injection and nalscue for for opioid use disorder; and perseris for schizophrenia. Its pipeline portfolio encompasses buprenorphine-based products, including INDV-2000 in pre-clinical phase for substance use disorder; IDV166001 in pre-clinical phase for substance use disorder; and INDV-1000 in pre-clinical phase for substance use disorder. Indivior offers products in the form of film, tablets, and subutex tabs. It offers its products in the US, Australia, Malaysia, France, Italy, Spain, Germany, Canada and the UK. Indivior is headquartered in Slough, the UK.

Indivior Plc Key Recent Developments

Oct 12,2021: Indivior to Announce Q3/9 Months YTD 2021 Results and Host a Presentation on October 28th
Jul 29,2021: Indivior Announces H1 and Q2 2021 Financial Results
Jul 29,2021: Indivior announces Half-year Report
Jul 14,2021: Indivior to Announce Q2/H1 2021 Results and Host a Presentation on July 29th
Jun 30,2021: Indivior Raises FY 2021 Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Indivior Plc - Key Facts
Indivior Plc - Key Employees
Indivior Plc - Key Employee Biographies
Indivior Plc - Major Products and Services
Indivior Plc - History
Indivior Plc - Company Statement
Indivior Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Indivior Plc - Business Description
Product Category: Perseris
Performance
Product Category: Sublingual/Other
Performance
Product Category: Sublocade
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
R&D Overview
Indivior Plc - Corporate Strategy
Indivior Plc - SWOT Analysis
SWOT Analysis - Overview
Indivior Plc - Strengths
Indivior Plc - Weaknesses
Indivior Plc - Opportunities
Indivior Plc - Threats
Indivior Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Indivior Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Oct 12, 2021: Indivior to Announce Q3/9 Months YTD 2021 Results and Host a Presentation on October 28th
Jul 29, 2021: Indivior Announces H1 and Q2 2021 Financial Results
Jul 29, 2021: Indivior announces Half-year Report
Jul 14, 2021: Indivior to Announce Q2/H1 2021 Results and Host a Presentation on July 29th
Jun 24, 2021: Indivior presents new data at the College on Problems of Drug Dependence (CPDD) 2021 Annual Conference
Jun 09, 2021: Indivior and Aelis enter $130m deal for cannabis addiction therapy
Jun 08, 2021: Indivior Extends Leadership Position In Substance Use Disorder Treatment With Exclusive Agreement For Leading Asset Targeting Cannabis-Related Disorders
Apr 29, 2021: Indivior Announces Q1 2021 Financial Results
Apr 29, 2021: INDIVIOR: 1st quarter results
Apr 29, 2021: Indivior applauds Biden Aadministration’s new Buprenorphine practice guidelines expanding access to treatment for opioid use disorder

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Indivior Plc, Key Facts
Indivior Plc, Key Employees
Indivior Plc, Key Employee Biographies
Indivior Plc, Major Products and Services
Indivior Plc, History
Indivior Plc, Subsidiaries
Indivior Plc, Key Competitors
Indivior Plc, Ratios based on current share price
Indivior Plc, Annual Ratios
Indivior Plc, Annual Ratios (Cont...1)
Indivior Plc, Annual Ratios (Cont...2)
Indivior Plc, Interim Ratios
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Indivior Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Indivior Plc, Performance Chart (2016 - 2020)
Indivior Plc, Ratio Charts
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Indivior Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021